Back to Test Catalogue

Estradiol and Estrone by LC-MS/MS, Serum/Plasma

Test ID: ESTRDP SP

Test

Aliases/Synonyms

E1; E2; Estrogens

Method

LC-MS/MS

Report Includes

Estrone; Estradiol

Specimens

Serum; Plasma

Clinical Utility

Simultaneous high-sensitivity determination of serum estrone and estradiol levels. Situations requiring either higher sensitivity estradiol measurement, estrone measurement, or both, including

  • As part of the diagnosis and workup of precocious and delayed puberty
  • As part of the diagnosis and workup of suspected disorders of sex steroid metabolism, (eg, aromatase deficiency and 17 alpha-hydroxylase deficiency)
  • As an adjunct to clinical assessment, imaging studies, and bone mineral density measurement in the fracture risk assessment of postmenopausal women
  • Monitoring low-dose female hormone replacement therapy in postmenopausal women
  • Monitoring antiestrogen therapy (eg, aromatase inhibitor therapy)

In conjunction with luteinizing hormone measurements, monitoring of estrogen replacement therapy in hypogonadal premenopausal women.
Evaluation of feminization, including gynecomastia, in males.
Diagnosis of estrogen-producing neoplasms.

Test Version

19-Jan-2026

Specimen

Specimens

Serum; Plasma

Collection Containers

Preferred

SST (Gold Top)

Acceptable

Na Heparin (Green Top); Lithium Heparin (Green Top)

Sample Volume

1.0 mL (preferred)

Minimum Volume

0.5 mL

Collection & Handling

Handling Information

Separate serum or plasma from cells within 2 hours of collection.

Stability

Ambient 1 day
Refrigerated 7 days
Frozen 180 days

Rejection Criteria

Hemolysis Present

Test Version

19-Jan-2026

Performance / Interpretation

Method

LC-MS/MS

Turnaround Time

8 days

Results

Name Units Reference Range Conversion Factor
Estradiol pmol/L
  • Female
    ≤14 days: ≤ 242
    Stage I (> 14 days and prepubertal): ≤ 74
    Stage II: ≤ 88
    Stage III: ≤ 221
    Stage IV: 55 - 312
    Stage V: 55 - 1287
    ≥ 19 years
    Follicular phase: 55 - 368
    Luteal phase: 257 - 1103
    Postmenopausal: ≤ 55
    Male
    ≤ 14 days: ≤ 194
    Stage I (> 14 days and prepubertal): ≤ 48
    Stage II: ≤ 59
    Stage III: ≤ 96
    Stage IV: ≤ 140
    Stage V: 37 - 147
    ≥ 19 years: 37-147
Limit of Quantitation: 5 pmol/L
Estrone pmol/L
  • Female
    ≤ 14 days: Not Established
    Stage I: (> 14 days and prepubertal): ≤ 108
    Stage II: 37 - 122
    Stage III: 55 - 160
    Stage IV: 59 - 285
    Stage V: 63 - 741
    ≥ 19 years
    Premenopausal: 63 - 741
    Postmenopausal: 25 - 148
    Male:≤ 14 days: Not Established
    Stage I: (> 14 days and prepubertal): ≤ 60
    Stage II: ≤ 82
    Stage III: 37 - 93
    Stage IV: 37 - 171
    Stage V: 37 - 222
    ≥ 19 years: 37-222
Upper reporting Limit: 10,000
Lower reporting Limit: 6.0

Test Version

19-Jan-2026

Interface / Setup

HL7 Interface Codes

Order Code Result Codes Units
ESTRDP SP Units 64548Estradiol pmol/L
64527Estrone pmol/L

Test Version

19-Jan-2026